The Effects of Chronic Δ-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) use on Cerebral Glucose Metabolism in Multiple Sclerosis: A Pilot Study.<div></div>Workman CD, Kindred JH, Boles Ponto LL, Kamholz J, Rudroff T.<br/>Appl Physiol Nutr Metab. 2019 Dec 16. doi: 10.1139/apnm-2019-0634. [Epub ahead of print]<div></div>PMID:31841355<div></div>Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways.<div></div>Al-Ghezi ZZ, Miranda K, Nagarkatti M, Nagarkatti PS.<br/>Front Immunol. 2019 Aug 21;10:1921. doi: 10.3389/fimmu.2019.01921. eCollection 2019.<div></div>PMID:31497013<br/>Free PMC Article<div></div>Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).<div></div>Meyer T, Funke A, Münch C, Kettemann D, Maier A, Walter B, Thomas A, Spittel S.<br/>BMC Neurol. 2019 Sep 7;19(1):222. doi: 10.1186/s12883-019-1443-y.<div></div>PMID:31493784<br/>Free PMC Article<div></div>Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.<div></div>Montero-Escribano P, Vila Silván C.<br/>Expert Rev Med Devices. 2019 Sep;16(9):835-840. doi: 10.1080/17434440.2019.1653182. Epub 2019 Aug 19.<div></div>PMID:31393179<div></div>[Progress in cannabis research from a pharmaceutical chemist's point of view].<div></div>Müller CE.<br/>Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Jul;62(7):818-824. doi: 10.1007/s00103-019-02964-4. Review. German. <div></div>PMID:31161229<div></div>Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies.<div></div>Akgün K, Essner U, Seydel C, Ziemssen T.<br/>J Cent Nerv Syst Dis. 2019 Mar 11;11:1179573519831997. doi: 10.1177/1179573519831997. eCollection 2019. Review.<div></div>PMID:30886530<br/>Free PMC Article<div></div>Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.<div></div>Patti F.<br/>Neurodegener Dis Manag. 2019 Apr;9(2s):3-7. doi: 10.2217/nmt-2018-0049. Epub 2019 Jan 18.<div></div>PMID:30657027<div></div>Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.<div></div>Marková J.<br/>Neurodegener Dis Manag. 2019 Apr;9(2s):9-13. doi: 10.2217/nmt-2018-0050. Epub 2019 Jan 18.<div></div>PMID:30657024<div></div>Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.<div></div>Ziemssen T.<br/>Neurodegener Dis Manag. 2019 Apr;9(2s):1-2. doi: 10.2217/nmt-2018-0048. Epub 2019 Jan 18.<div></div>PMID:30657019<div></div>Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal.<div></div>Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E.<br/>Mult Scler Relat Disord. 2019 Jan;27:383-390. doi: 10.1016/j.msard.2018.11.022. Epub 2018 Nov 20.<div></div>PMID:30502644<div></div>Cannabis Therapeutics and the Future of Neurology.<div></div>Russo EB.<br/>Front Integr Neurosci. 2018 Oct 18;12:51. doi: 10.3389/fnint.2018.00051. eCollection 2018.<div></div>PMID:30405366<br/>Free PMC Article<div></div>Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice.<div></div>Gallily R, Yekhtin Z.<br/>Inflammopharmacology. 2019 Feb;27(1):167-173. doi: 10.1007/s10787-018-0536-3. Epub 2018 Oct 5.<div></div>PMID:30291491<div></div>A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.<div></div>Arroyo González R.<br/>Expert Rev Neurother. 2018 Oct;18(10):785-791. doi: 10.1080/14737175.2018.1510772. Epub 2018 Sep 20. Review.<div></div>PMID:30235965<div></div>Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings.<div></div>Flachenecker P, Saccà F, Vila C.<br/>Case Rep Neurol. 2018 Jul 12;10(2):169-176. doi: 10.1159/000490376. eCollection 2018 May-Aug.<div></div>PMID:30140216<br/>Free PMC Article<div></div>Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells.<div></div>Elliott DM, Singh N, Nagarkatti M, Nagarkatti PS.<br/>Front Immunol. 2018 Aug 3;9:1782. doi: 10.3389/fimmu.2018.01782. eCollection 2018.<div></div>PMID:30123217<br/>Free PMC Article<div></div>Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.<div></div>Contin M, Mancinelli L, Perrone A, Sabattini L, Mohamed S, Scandellari C, Foschi M, Vacchiano V, Lugaresi A, Riva R.<br/>Clin Neuropharmacol. 2018 Sep/Oct;41(5):171-176. doi: 10.1097/WNF.0000000000000294.<div></div>PMID:30024443<div></div>Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.<div></div>Noel C.<br/>Ment Health Clin. 2018 Mar 23;7(1):29-38. doi: 10.9740/mhc.2017.01.029. eCollection 2017 Jan.<div></div>PMID:29955495<br/>Free PMC Article<div></div>Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials.<div></div>Turri M, Teatini F, Donato F, Zanette G, Tugnoli V, Deotto L, Bonetti B, Squintani G.<br/>Medicines (Basel). 2018 Jun 21;5(3). pii: E59. doi: 10.3390/medicines5030059.<div></div>PMID:29933552<br/>Free PMC Article<div></div>Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.<div></div>Mallada Frechín J.<br/>Neurodegener Dis Manag. 2018 Jun;8(3):151-159. doi: 10.2217/nmt-2017-0055. Epub 2018 May 31.<div></div>PMID:29851356<div></div>Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.<div></div>Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C.<br/>Int J Neurosci. 2019 Feb;129(2):119-128. doi: 10.1080/00207454.2018.1481066. Epub 2018 Sep 13.<div></div>PMID:29792372<div></div>Review of the neurological benefits of phytocannabinoids.<div></div>Maroon J, Bost J.<br/>Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18. eCollection 2018. Review.<div></div>PMID:29770251<br/>Free PMC Article<div></div>The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.<div></div>Celius EG, Vila C.<br/>Brain Behav. 2018 Apr 6;8(5):e00962. doi: 10.1002/brb3.962. eCollection 2018 May. Review.<div></div>PMID:29761015<br/>Free PMC Article<div></div>Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.<div></div>Lus G, Cantello R, Danni MC, Rini A, Sarchielli P, Tassinari T, Signoriello E.<br/>Neurodegener Dis Manag. 2018 Apr;8(2):105-113. doi: 10.2217/nmt-2017-0056. Epub 2018 Apr 23.<div></div>PMID:29683408<div></div>Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy.<div></div>Navarrete C, Carrillo-Salinas F, Palomares B, Mecha M, Jiménez-Jiménez C, Mestre L, Feliú A, Bellido ML, Fiebich BL, Appendino G, Calzado MA, Guaza C, Muñoz E.<br/>J Neuroinflammation. 2018 Mar 1;15(1):64. doi: 10.1186/s12974-018-1103-y.<div></div>PMID:29495967<br/>Free PMC Article<div></div>What's new in multiple sclerosis spasticity research? Poster session highlights.<div></div>Linker R.<br/>Neurodegener Dis Manag. 2017 Nov;7(6s):51-53. doi: 10.2217/nmt-2017-0043.<div></div>PMID:29143588<div></div>Multiple sclerosis symptoms and spasticity management: new data.<div></div>Izquierdo G.<br/>Neurodegener Dis Manag. 2017 Nov;7(6s):7-11. doi: 10.2217/nmt-2017-0034. Review.<div></div>PMID:29143581<div></div>Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.<div></div>Krcevski-Skvarc N, Wells C, Häuser W.<br/>Eur J Pain. 2018 Mar;22(3):440-454. doi: 10.1002/ejp.1147. Epub 2017 Nov 13.<div></div>PMID:29134767<div></div>Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation.<div></div>Zgair A, Lee JB, Wong JCM, Taha DA, Aram J, Di Virgilio D, McArthur JW, Cheng YK, Hennig IM, Barrett DA, Fischer PM, Constantinescu CS, Gershkovich P.<br/>Sci Rep. 2017 Nov 6;7(1):14542. doi: 10.1038/s41598-017-15026-z.<div></div>PMID:29109461<br/>Free PMC Article<div></div>THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.<div></div>Maniscalco GT, Aponte R, Bruzzese D, Guarcello G, Manzo V, Napolitano M, Moreggia O, Chiariello F, Florio C.<br/>Neurol Sci. 2018 Jan;39(1):97-102. doi: 10.1007/s10072-017-3148-6. Epub 2017 Oct 19.<div></div>PMID:29052091<div></div>Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid.<div></div>Kozela E, Juknat A, Vogel Z.<br/>Int J Mol Sci. 2017 Jul 31;18(8). pii: E1669. doi: 10.3390/ijms18081669. Review.<div></div>PMID:28788104<br/>Free PMC Article<div></div>Neurological Aspects of Medical Use of Cannabidiol.<div></div>Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Cas RD, Ippolito FM, Calapai G.<br/>CNS Neurol Disord Drug Targets. 2017;16(5):541-553. doi: 10.2174/1871527316666170413114210. Review.<div></div>PMID:28412918<div></div>Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.<div></div>Keating GM.<br/>Drugs. 2017 Apr;77(5):563-574. doi: 10.1007/s40265-017-0720-6. Review.<div></div>PMID:28293911<div></div>Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?<div></div>Maccarrone M, Maldonado R, Casas M, Henze T, Centonze D.<br/>Expert Rev Clin Pharmacol. 2017 Apr;10(4):443-455. doi: 10.1080/17512433.2017.1292849. Epub 2017 Feb 28. Review.<div></div>PMID:28276775<div></div>Phytochemistry of Cannabis sativa L.<div></div>ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A.<br/>Prog Chem Org Nat Prod. 2017;103:1-36. doi: 10.1007/978-3-319-45541-9_1. Review.<div></div>PMID:28120229<div></div>An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray.<div></div>Etges T, Karolia K, Grint T, Taylor A, Lauder H, Daka B, Wright S.<br/>Ther Clin Risk Manag. 2016 Nov 11;12:1667-1675. eCollection 2016.<div></div>PMID:27956834<br/>Free PMC Article<div></div>Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis.<div></div>Giacoppo S, Pollastro F, Grassi G, Bramanti P, Mazzon E.<br/>Fitoterapia. 2017 Jan;116:77-84. doi: 10.1016/j.fitote.2016.11.010. Epub 2016 Nov 25.<div></div>PMID:27890794<div></div>What is new in multiple sclerosis spasticity research? Poster session highlights.<div></div>Ghezzi A.<br/>Neurodegener Dis Manag. 2016 Dec;6(6s):45-47.<div></div>PMID:27874498<div></div>Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the "weed," a pharmacodynamic discussion.<div></div>Boggs DL, Peckham A, Boggs AA, Ranganathan M.<br/>Ment Health Clin. 2016 Nov 3;6(6):277-284. doi: 10.9740/mhc.2016.11.277. eCollection 2016 Nov.<div></div>PMID:29955482<br/>Free PMC Article<div></div>Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.<div></div>Squintani G, Donato F, Turri M, Deotto L, Teatini F, Moretto G, Erro R.<br/>J Neurol Sci. 2016 Nov 15;370:263-268. doi: 10.1016/j.jns.2016.09.054. Epub 2016 Sep 28.<div></div>PMID:27772772<div></div>Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.<div></div>Vermersch P, Trojano M.<br/>Eur Neurol. 2016;76(5-6):216-226. Epub 2016 Oct 13. Erratum in: Eur Neurol. 2016;76(5-6):226. <div></div>PMID:27732980<div></div>Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.<div></div>Kozela E, Juknat A, Gao F, Kaushansky N, Coppola G, Vogel Z.<br/>J Neuroinflammation. 2016 Jun 3;13(1):136. doi: 10.1186/s12974-016-0603-x.<div></div>PMID:27256343<br/>Free PMC Article<div></div>Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.<div></div>Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group.<br/>J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591. Epub 2016 May 9.<div></div>PMID:27160523<br/>Free PMC Article<div></div>Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.<div></div>Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L.<br/>Eur Neurol. 2016;75(5-6):236-43. doi: 10.1159/000445943. Epub 2016 May 10.<div></div>PMID:27160412<div></div>The therapeutic use of cannabinoids: Forensic aspects.<div></div>Indorato F, Liberto A, Ledda C, Romano G, Barbera N.<br/>Forensic Sci Int. 2016 Aug;265:200-3. doi: 10.1016/j.forsciint.2016.03.031. Epub 2016 Mar 23.<div></div>PMID:27038587<div></div>The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.<div></div>Marinelli L, Mori L, Canneva S, Colombano F, Currà A, Fattapposta F, Bandini F, Capello E, Abbruzzese G, Trompetto C.<br/>Int Clin Psychopharmacol. 2016 Jul;31(4):232-9. doi: 10.1097/YIC.0000000000000126.<div></div>PMID:27003093<div></div>A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.<div></div>Wertlake PT, Henson MD.<br/>J Pain Res. 2016 Feb 12;9:81-5. doi: 10.2147/JPR.S96856. eCollection 2016.<div></div>PMID:26929665<br/>Free PMC Article<div></div>Cannabinoids: Medical implications.<div></div>Schrot RJ, Hubbard JR.<br/>Ann Med. 2016;48(3):128-41. doi: 10.3109/07853890.2016.1145794. Epub 2016 Feb 25. Review.<div></div>PMID:26912385<div></div>THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.<div></div>Fernández Ó.<br/>Eur Neurol. 2016;75 Suppl 1:1-3. doi: 10.1159/000444234. Epub 2016 Feb 23. Review.<div></div>PMID:26901342<br/>Free Article<div></div>Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.<div></div>Zettl UK, Rommer P, Hipp P, Patejdl R.<br/>Ther Adv Neurol Disord. 2016 Jan;9(1):9-30. doi: 10.1177/1756285615612659. Review.<div></div>PMID:26788128<br/>Free PMC Article<div></div>A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.<div></div>Gras A, Broughton J.<br/>Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):771-779. Epub 2016 Feb 26.<div></div>PMID:26750641<div></div>Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis.<div></div>Giacoppo S, Soundara Rajan T, Galuppo M, Pollastro F, Grassi G, Bramanti P, Mazzon E.<br/>Eur Rev Med Pharmacol Sci. 2015 Dec;19(24):4906-19.<div></div>PMID:26744883<br/>Free Article<div></div>Advances in the management of MS symptoms: recently proposed clinical management algorithms.<div></div>Vermersch P.<br/>Neurodegener Dis Manag. 2015;5(6 Suppl):23-6. doi: 10.2217/nmt.15.57. Review.<div></div>PMID:26611268<div></div>Advances in the management of MS symptoms: real-life evidence.<div></div>Trojano M.<br/>Neurodegener Dis Manag. 2015;5(6 Suppl):19-21. doi: 10.2217/nmt.15.66. Review.<div></div>PMID:26611267<div></div>Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.<div></div>Paolicelli D, Direnzo V, Manni A, D'Onghia M, Tortorella C, Zoccolella S, Di Lecce V, Iaffaldano A, Trojano M.<br/>J Clin Pharmacol. 2016 Jul;56(7):845-51. doi: 10.1002/jcph.670. Epub 2015 Dec 30.<div></div>PMID:26608223<div></div>The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.<div></div>Moreno-Martet M, Feliú A, Espejo-Porras F, Mecha M, Carrillo-Salinas FJ, Fernández-Ruiz J, Guaza C, de Lago E.<br/>Mult Scler Relat Disord. 2015 Nov;4(6):505-11. doi: 10.1016/j.msard.2015.08.001. Epub 2015 Aug 5.<div></div>PMID:26590655<div></div>Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.<div></div>Trojano M, Vila C.<br/>Eur Neurol. 2015;74(3-4):178-85. doi: 10.1159/000441619. Epub 2015 Nov 17.<div></div>PMID:26571097<div></div>A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.<div></div>Giacoppo S, Galuppo M, Pollastro F, Grassi G, Bramanti P, Mazzon E.<br/>Daru. 2015 Oct 21;23:48. doi: 10.1186/s40199-015-0131-8.<div></div>PMID:26489494<br/>Free PMC Article<div></div>Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation.<div></div>Stanley CP, Hind WH, Tufarelli C, O'Sullivan SE.<br/>Cardiovasc Res. 2015 Sep 1;107(4):568-78. doi: 10.1093/cvr/cvv179. Epub 2015 Jun 19.<div></div>PMID:26092099<br/>Free PMC Article<div></div>Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!<div></div>Russo M, Rifici C, Sessa E, D'Aleo G, Bramanti P, Calabrò RS.<br/>Daru. 2015 Apr 17;23:25. doi: 10.1186/s40199-015-0109-6.<div></div>PMID:25881038<br/>Free PMC Article<div></div>Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells.<div></div>Kozela E, Juknat A, Kaushansky N, Ben-Nun A, Coppola G, Vogel Z.<br/>J Neuroinflammation. 2015 Mar 15;12:52. doi: 10.1186/s12974-015-0273-0.<div></div>PMID:25880134<br/>Free PMC Article<div></div>A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.<div></div>Feliú A, Moreno-Martet M, Mecha M, Carrillo-Salinas FJ, de Lago E, Fernández-Ruiz J, Guaza C.<br/>Br J Pharmacol. 2015 Jul;172(14):3579-95. doi: 10.1111/bph.13159. Epub 2015 May 20.<div></div>PMID:25857324<br/>Free PMC Article<div></div>Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice.<div></div>Rahimi A, Faizi M, Talebi F, Noorbakhsh F, Kahrizi F, Naderi N.<br/>Neuroscience. 2015 Apr 2;290:279-87. doi: 10.1016/j.neuroscience.2015.01.030. Epub 2015 Jan 28.<div></div>PMID:25637488<div></div>Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.<div></div>Di Marzo V, Centonze D.<br/>CNS Neurosci Ther. 2015 Mar;21(3):215-21. doi: 10.1111/cns.12358. Epub 2014 Dec 4. Review.<div></div>PMID:25475413<br/>Free PMC Article<div></div>Medical marijuana in neurology.<div></div>Benbadis SR, Sanchez-Ramos J, Bozorg A, Giarratano M, Kalidas K, Katzin L, Robertson D, Vu T, Smith A, Zesiewicz T.<br/>Expert Rev Neurother. 2014 Dec;14(12):1453-65. doi: 10.1586/14737175.2014.985209. Review.<div></div>PMID:25427150<div></div>Cannabidiol: promise and pitfalls.<div></div>Welty TE, Luebke A, Gidal BE.<br/>Epilepsy Curr. 2014 Sep;14(5):250-2. doi: 10.5698/1535-7597-14.5.250.<div></div>PMID:25346628<br/>Free PMC Article<div></div>Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.<div></div>Moreno Torres I, Sanchez AJ, Garcia-Merino A.<br/>Expert Rev Neurother. 2014 Nov;14(11):1243-50. doi: 10.1586/14737175.2014.971758. Review.<div></div>PMID:25331416<div></div>Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.<div></div>Trojano M, Celius EG, Donzé C, Izquierdo G, Patti F, Pöhlau D.<br/>Eur Neurol. 2014;72 Suppl 1:15-9. doi: 10.1159/000367619. Epub 2014 Sep 26.<div></div>PMID:25278119<br/>Free Article<div></div>Advances in the management of MS spasticity: recent observational studies.<div></div>Fernández O.<br/>Eur Neurol. 2014;72 Suppl 1:12-4. doi: 10.1159/000367618. Epub 2014 Sep 26.<div></div>PMID:25278118<br/>Free Article<div></div>Advances in the management of multiple sclerosis spasticity: recent clinical trials.<div></div>Fernández O.<br/>Eur Neurol. 2014;72 Suppl 1:9-11. doi: 10.1159/000367616. Epub 2014 Sep 26.<div></div>PMID:25278117<br/>Free Article<div></div>Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways.<div></div>Centonze D.<br/>Eur Neurol. 2014;72 Suppl 1:6-8. doi: 10.1159/000367615. Epub 2014 Sep 26.<div></div>PMID:25278116<br/>Free Article<div></div>Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.<div></div>Freidel M, Tiel-Wilck K, Schreiber H, Prechtl A, Essner U, Lang M.<br/>Acta Neurol Scand. 2015 Jan;131(1):9-16. doi: 10.1111/ane.12287. Epub 2014 Sep 11.<div></div>PMID:25208898<div></div>The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.<div></div>Molnar A, Fu S, Lewis J, Allsop DJ, Copeland J.<br/>Forensic Sci Int. 2014 May;238:113-9. doi: 10.1016/j.forsciint.2014.03.004. Epub 2014 Mar 12.<div></div>PMID:24699310<div></div>Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.<div></div>Syed YY, McKeage K, Scott LJ.<br/>Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Review.<div></div>PMID:24671907<div></div>Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.<div></div>Flachenecker P, Henze T, Zettl UK.<br/>Eur Neurol. 2014;71(5-6):271-9. doi: 10.1159/000357427. Epub 2014 Feb 12.<div></div>PMID:24525548<div></div>Who benefits most from THC:CBD spray? Learning from clinical experience.<div></div>Koehler J.<br/>Eur Neurol. 2014;71 Suppl 1:10-5. doi: 10.1159/000357743. Epub 2014 Jan 22.<div></div>PMID:24457847<br/>Free Article<div></div>THC:CBD spray and MS spasticity symptoms: data from latest studies.<div></div>Rekand T.<br/>Eur Neurol. 2014;71 Suppl 1:4-9. doi: 10.1159/000357742. Epub 2014 Jan 22. Review.<div></div>PMID:24457846<br/>Free Article<div></div>Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.<div></div>Koehler J, Feneberg W, Meier M, Pöllmann W.<br/>Int J Neurosci. 2014 Sep;124(9):652-6. doi: 10.3109/00207454.2013.877460. Epub 2014 Jan 23.<div></div>PMID:24392812<div></div>A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK.<div></div>Potter DJ.<br/>Drug Test Anal. 2014 Jan-Feb;6(1-2):31-8. doi: 10.1002/dta.1531. Epub 2013 Sep 30. Review.<div></div>PMID:24115748<div></div>Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.<div></div>Lorente Fernández L, Monte Boquet E, Pérez-Miralles F, Gil Gómez I, Escutia Roig M, Boscá Blasco I, Poveda Andrés JL, Casanova-Estruch B.<br/>Neurologia. 2014 Jun;29(5):257-60. doi: 10.1016/j.nrl.2013.06.014. Epub 2013 Sep 10. English, Spanish. <div></div>PMID:24035293<br/>Free Article<div></div>Cannabinoids decrease the th17 inflammatory autoimmune phenotype.<div></div>Kozela E, Juknat A, Kaushansky N, Rimmerman N, Ben-Nun A, Vogel Z.<br/>J Neuroimmune Pharmacol. 2013 Dec;8(5):1265-76. doi: 10.1007/s11481-013-9493-1. Epub 2013 Jul 28.<div></div>PMID:23892791<div></div>Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.<div></div>Mecha M, Feliú A, Iñigo PM, Mestre L, Carrillo-Salinas FJ, Guaza C.<br/>Neurobiol Dis. 2013 Nov;59:141-50. doi: 10.1016/j.nbd.2013.06.016. Epub 2013 Jul 11.<div></div>PMID:23851307<br/>Free Article<div></div>A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray.<div></div>Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, Stott CG, Wright S, White L, Duncombe P, Chen CF.<br/>Clin Pharmacol Drug Dev. 2013 Jul;2(3):285-94. doi: 10.1002/cpdd.36. Epub 2013 May 14.<div></div>PMID:27121791<div></div>Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.<div></div>Duchi S, Ovadia H, Touitou E.<br/>J Neuroimmunol. 2013 May 15;258(1-2):32-40. doi: 10.1016/j.jneuroim.2013.02.013. Epub 2013 Mar 18.<div></div>PMID:23517929<div></div>A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.<div></div>Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S.<br/>J Neurol. 2013 Apr;260(4):984-97. doi: 10.1007/s00415-012-6739-4. Epub 2012 Nov 21.<div></div>PMID:23180178<div></div>Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice.<div></div>Karmaus PW, Wagner JG, Harkema JR, Kaminski NE, Kaplan BL.<br/>J Immunotoxicol. 2013 Jul-Sep;10(3):321-8. doi: 10.3109/1547691X.2012.741628. Epub 2012 Nov 23.<div></div>PMID:23173851<br/>Free PMC Article<div></div>A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis.<div></div>Granja AG, Carrillo-Salinas F, Pagani A, Gómez-Cañas M, Negri R, Navarrete C, Mecha M, Mestre L, Fiebich BL, Cantarero I, Calzado MA, Bellido ML, Fernandez-Ruiz J, Appendino G, Guaza C, Muñoz E.<br/>J Neuroimmune Pharmacol. 2012 Dec;7(4):1002-16. doi: 10.1007/s11481-012-9399-3. Epub 2012 Sep 14.<div></div>PMID:22971837<div></div>Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.<div></div>Serpell MG, Notcutt W, Collin C.<br/>J Neurol. 2013 Jan;260(1):285-95. doi: 10.1007/s00415-012-6634-z. Epub 2012 Aug 10.<div></div>PMID:22878432<div></div>Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress.<div></div>Mecha M, Torrao AS, Mestre L, Carrillo-Salinas FJ, Mechoulam R, Guaza C.<br/>Cell Death Dis. 2012 Jun 28;3:e331. doi: 10.1038/cddis.2012.71.<div></div>PMID:22739983<br/>Free PMC Article<div></div>Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.<div></div>Vicente-Valor MI, Garcia-Llopis P, Mejia Andujar L, Antonino de la Camara G, García del Busto N, Lopez Tinoco MJ, Quintana Vergara B, Peiro Vilaplana C, Dominguez Moran JA, Sánchez Alcaraz A.<br/>J Clin Pharm Ther. 2013 Feb;38(1):71-3. doi: 10.1111/j.1365-2710.2012.01365.x. Epub 2012 Jun 21.<div></div>PMID:22726074<div></div>THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.<div></div>Sastre-Garriga J, Vila C, Clissold S, Montalban X.<br/>Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Epub 2011 Apr 1. Review.<div></div>PMID:21456949<div></div>Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice.<div></div>Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, Ben-Nun A, Juknat A, Vogel Z.<br/>Br J Pharmacol. 2011 Aug;163(7):1507-19. doi: 10.1111/j.1476-5381.2011.01379.x.<div></div>PMID:21449980<br/>Free PMC Article<div></div><br/>Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.<div></div>Lakhan SE, Rowland M.<br/>BMC Neurol. 2009 Dec 4;9:59. doi: 10.1186/1471-2377-9-59. Review.<div></div>PMID:19961<br/>